Welldoc Cements AI Leadership with Dedicated AI Lab and 100+ Clinical Publications

Welldoc's Strategic Investment Accelerates Research and Development of Novel AI-Powered Hyper-personalization Capabilities at Scale

COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced the formal launch of the Welldoc AI Lab and confirmed a significant milestone of over 100 peer-reviewed clinical publications, including 43 dedicated to advanced AI. Together with the company's 11 FDA clearances and 60 patents, these achievements underscore Welldoc's unmatched commitment to clinical rigor and evidence-based innovation.

Welldoc's AI delivers measurable improvements in real-world settings, not just in theory, establishing the company as the leading clinically validated health technology partner. The AI Lab represents a clear focus on moving beyond generalized AI solutions. It is designed to accelerate the next generation of healthcare, driving truly personalized, clinically validated care.

“Welldoc's investments in AI and clinical validation are essential to build trust as we transition care navigation from a generalized service to one that is personalized based on your data,” said Aneesh Chopra, the first U.S. Chief Technology Officer and strategic advisor to Welldoc. "This approach has the potential to scale responsibly by increasing access to a service that improves health outcomes at a fraction of the cost.”

The AI Lab’s core strategy involves enhancing the company’s proprietary data intelligence platform by driving a critical expansion beyond Large Language Models (LLMs) to include specialized Large Sensor Models (LSMs), novel hybrid machine learning and state of the art transformer-based approaches.

These cutting-edge initiatives, backed by academic partnerships with leaders like the Johns Hopkins University Center for Digital Health and AI (CDHAI) and the Vellore Institute of Technology, are foundational to Welldoc’s future-forward leadership in building first-in-class AI capabilities and increased intellectual property that is driving the industry forward.

"The future of healthcare must be AI-driven, but it cannot compromise on clinical standards," said Anand Iyer, PhD, MBA, Chief AI Officer of Welldoc. "Given our significant experience building regulatory-grade AI and our foundation of over 100 clinical publications, Welldoc is engineered to lead this transformation responsibly. The Welldoc AI Lab's mandate is clear: harness the power of specialized, generative AI to deliver predictive, personalized care that individuals and clinicians can trust and rely on, without sacrificing the safety and rigor that healthcare demands.”

Current research priorities include leveraging sensor data to predict health trajectories, optimizing engagement patterns for sustained behavior change, and addressing the complexities of obesity management in the era of GLP-1 medications. This reflects the complex areas where Welldoc's extensive experience in cardiometabolic care provides unique clinical insights. Concepts and research developed through the AI Lab directly lead to new platform capabilities, including the forthcoming introduction of Simon, an AI chatbot and insights engine, designed to further personalize the experience toward building better habits.

The company’s leadership in cutting-edge AI is further validated by its recognition as an Early Adopter in the CMS Health Tech Ecosystem initiative, and being named one of TIME and Statista's World's Top HealthTech Companies of 2025 for leadership in AI and data analytics.

At its core, Welldoc is bridging the gaps that have long fragmented healthcare: siloed data, episodic care, and disconnected experiences. By combining purpose-built AI with deep clinical expertise and a device-agnostic platform, Welldoc creates continuous, personalized support that extends care beyond office visits into daily lives. Welldoc invites innovators, providers, and partners to join in this new chapter of defining the health experience of the future, powered by profound data insights and absolute clinical trust.

About Welldoc

Welldoc® is an AI-powered health technology leader committed to connecting people to better, more personalized cardiometabolic care. The company's digital health platform delivers a unified experience for individuals managing diabetes, obesity (including GLP-1 support), hypertension, heart failure, and complex comorbidities including diabetes in pregnancy, sleep apnea, chronic kidney disease (CKD), and metabolic dysfunction-associated steatohepatitis (MASH).

The foundation of Welldoc's solution is healthcare-ready AI, a purpose-built engine grounded in unmatched clinical rigor, with 11 FDA clearances, 60 patents, and more than 100 peer-reviewed publications demonstrating clinical effectiveness and safety. The platform's architecture allows individuals to connect to over 400 devices and data sources, while also integrating seamlessly with electronic health record (EHR) systems, to enable comprehensive data interoperability across care settings.

Welldoc partners across multiple healthcare sectors—including life sciences companies, health plans, health systems, and employers—to drive innovative health programs, improved patient outcomes, and reduced costs at scale. The company has been recognized as a leader in healthcare innovation, named one of TIME and Statista's World's Top HealthTech Companies and awarded "Best Overall Digital Health Company" by MedTech Breakthrough™ for multiple consecutive years. Welldoc is strategically aligned with federal modernization efforts, including being named an early adopter in the CMS 2025 Health Tech Ecosystem Initiative. This ensures the company’s AI-powered solutions support critical programs like the CMS Rural Health Transformation Program (RHTP) focused on rural healthcare access. For more information, visit www.welldoc.com.